// Haibo Wang 1, 2, 3, 4, * , Lide Tao 1, 3, * , Feng Jin 1, 2, 3, 4, * , Hao Gu 3, 4 , Xiaojun Dai 3, 4 , Tengyang Ni 1, 2, 3, 4 , Jun Feng 1, 2, 3, 4 , Yanbing Ding 1 , Weiming Xiao 1 , Yayun Qian 3, 4 and Yanqing Liu 1, 2, 3, 4 1 The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, China 2 Clinical Medicine College of Yangzhou University, Yangzhou 225000, China 3 The State Administration of Traditional Chinese Medicine Key Laboratory of Toxic Pathogens-Based Therapeutic Approaches to Gastric Cancer, Yangzhou 225000, China 4 Institution of Combining Chinese Traditional and Western Medicine, Medical College, Yangzhou University, Yangzhou 225000, China * These authors have contributed equally to this work and should be considered as co-first authors Correspondence to: Yanqing Liu, email: yzumpi@163.com Yayun Qian, email: yyqian@yzu.edu.cn Keywords: CFL1, gastric cancer (GC), cytoskeleton rearrangement, epithelial-mesenchymal transition (EMT) Received: January 12, 2017 Accepted: March 02, 2017 Published: March 27, 2017 ABSTRACT Epithelial-mesenchymal transition (EMT) is an important biological process whereby malignant tumor cells obtain the ability to migrate, invade, resist apoptosis and degrade the extracellular matrix. We found that Cofilin1 (CFL1) expression was elevated in clinical gastric cancer specimens and correlated with biomarkers of EMT in BGC-823 gastric cancer cells. BGC-823 cells exhibited EMT phenotypes and increased metastatic ability when induced by TGF-β1. By contrast, BGC-823 cells transfected with Lv-siRNA-CFL1 did not exhibit EMT phenotypes under the same inducing conditions. As CFL1 expression increased, EMT cell filopodia stretched out. In addition, the ultrastructures observed using transmission electron microscopy indicated that silencing of CFL1 markedly inhibited depolymerization of fibrous actin and cytoskeletal reorganization during EMT. Similar results were obtained in vivo . These findings demonstrate that CFL1 induces EMT by promoting cytoskeletal rearrangement. Our results may provide the basis for developing new anticancer drugs to inhibit CFL1.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: